ALK and non-small cell lung carcinoma: However, according to a meta-analysis evaluating the benefit-predicting factors of metastatic NSCLC, chemoimmunotherapy led to longer PFS regardless of EGFR or ALK status, whereas Impower130 exhibited no significant PFS superiority with non-bevacizumab-based regimens in EGFR/ALK+ subgroups (88, 89).